z-logo
open-access-imgOpen Access
Dynamin inhibition causes context-dependent cell death of leukemia and lymphoma cells
Author(s) -
Christopher von Beek,
Linnéa Alriksson,
Josefine Palle,
Ann-Marie Gustafson,
Mirjana Grujić,
Fabio Rabelo Melo,
Mikael E. Sellin,
Gunnar Pejler
Publication year - 2021
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0256708
Subject(s) - dynamin , cancer research , leukemia , acute leukemia , bone marrow , apoptosis , cancer cell , programmed cell death , lymphoma , medicine , cancer , biology , endocytosis , immunology , receptor , biochemistry
Current chemotherapy for treatment of pediatric acute leukemia, although generally successful, is still a matter of concern due to treatment resistance, relapses and life-long side effects for a subset of patients. Inhibition of dynamin, a GTPase involved in clathrin-mediated endocytosis and regulation of the cell cycle, has been proposed as a potential anti-cancer regimen, but the effects of dynamin inhibition on leukemia cells has not been extensively addressed. Here we adopted single cell and whole-population analysis by flow cytometry and live imaging, to assess the effect of dynamin inhibition (Dynasore, Dyngo-4a, MitMAB) on pediatric acute leukemia cell lines (CCRF-CEM and THP-1), human bone marrow biopsies from patients diagnosed with acute lymphoblastic leukemia (ALL), as well as in a model of lymphoma (EL4)-induced tumor growth in mice. All inhibitors suppressed proliferation and induced pronounced caspase-dependent apoptotic cell death in CCRF-CEM and THP-1 cell lines. However, the inhibitors showed no effect on bone marrow biopsies, and did not prevent EL4-induced tumor formation in mice. We conclude that dynamin inhibition affects highly proliferating human leukemia cells. These findings form a basis for evaluation of the potential, and constraints, of employing dynamin inhibition in treatment strategies against leukemia and other malignancies.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here